Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial

The national surgical adjuvant study of breast cancer 02

Shozo Ohsumi, Kojiro Shimozuma, Yasuo Ohashi, Ayano Takeuchi, Kimito Suemasu, Masaru Kuranami, Shinji Ohno, Toru Watanabe

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: To elucidate the time course of taxane-induced edema which may affect the patients' quality of life (QOL). Patients and Methods: Our study included the first 300 Japanese patients assigned to 1 of 4 regimens using docetaxel (DTX) or paclitaxel (PTX) by 1:1:1:1 in a randomized controlled trial to evaluate the efficacy of adjuvant therapies for node-positive breast cancer. Patients' QOL was prospectively assessed by the Functional Assessment of Cancer Therapy (FACT)-breast and-taxane (FACT-T) subscale. The scores of FACT items regarding edema and body weight were used as indicators of edema. Results: The scores for 'anasarca', 'edema of the hands' and 'edema of the legs and feet' of the FACT-T subscale worsened up to 1-2 months after chemotherapy, and body weights increased remarkably until cycle 8 in patients treated with DTX alone (75 mg/m 2, 8 cycles, every 3 weeks). Edema-related symptoms and body weight were relatively stable in the other treatment groups. There were statistically significant differences in the scores of those items and in the changes of body weight both between the DTX-alone group and the other three groups combined, and between the groups using DTX and those using PTX. Conclusion: Many patients receiving DTX for >4 cycles suffered significantly from edema.

Original languageEnglish
Pages (from-to)131-138
Number of pages8
JournalOncology
Volume82
Issue number3
DOIs
Publication statusPublished - 2012 Apr
Externally publishedYes

Fingerprint

docetaxel
Adjuvant Chemotherapy
Edema
Randomized Controlled Trials
Breast Neoplasms
Body Weight
Paclitaxel
Quality of Life
Therapeutics
Body Weight Changes
taxane
Foot
Neoplasms
Leg
Hand
Drug Therapy

Keywords

  • Adjuvant chemotherapy
  • Breast cancer
  • Chemotherapy-induced edema
  • Quality of life
  • Taxane

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial : The national surgical adjuvant study of breast cancer 02. / Ohsumi, Shozo; Shimozuma, Kojiro; Ohashi, Yasuo; Takeuchi, Ayano; Suemasu, Kimito; Kuranami, Masaru; Ohno, Shinji; Watanabe, Toru.

In: Oncology, Vol. 82, No. 3, 04.2012, p. 131-138.

Research output: Contribution to journalArticle

Ohsumi, Shozo ; Shimozuma, Kojiro ; Ohashi, Yasuo ; Takeuchi, Ayano ; Suemasu, Kimito ; Kuranami, Masaru ; Ohno, Shinji ; Watanabe, Toru. / Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial : The national surgical adjuvant study of breast cancer 02. In: Oncology. 2012 ; Vol. 82, No. 3. pp. 131-138.
@article{ceee857b26b74bcdab940ddee71ea5ee,
title = "Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The national surgical adjuvant study of breast cancer 02",
abstract = "Objective: To elucidate the time course of taxane-induced edema which may affect the patients' quality of life (QOL). Patients and Methods: Our study included the first 300 Japanese patients assigned to 1 of 4 regimens using docetaxel (DTX) or paclitaxel (PTX) by 1:1:1:1 in a randomized controlled trial to evaluate the efficacy of adjuvant therapies for node-positive breast cancer. Patients' QOL was prospectively assessed by the Functional Assessment of Cancer Therapy (FACT)-breast and-taxane (FACT-T) subscale. The scores of FACT items regarding edema and body weight were used as indicators of edema. Results: The scores for 'anasarca', 'edema of the hands' and 'edema of the legs and feet' of the FACT-T subscale worsened up to 1-2 months after chemotherapy, and body weights increased remarkably until cycle 8 in patients treated with DTX alone (75 mg/m 2, 8 cycles, every 3 weeks). Edema-related symptoms and body weight were relatively stable in the other treatment groups. There were statistically significant differences in the scores of those items and in the changes of body weight both between the DTX-alone group and the other three groups combined, and between the groups using DTX and those using PTX. Conclusion: Many patients receiving DTX for >4 cycles suffered significantly from edema.",
keywords = "Adjuvant chemotherapy, Breast cancer, Chemotherapy-induced edema, Quality of life, Taxane",
author = "Shozo Ohsumi and Kojiro Shimozuma and Yasuo Ohashi and Ayano Takeuchi and Kimito Suemasu and Masaru Kuranami and Shinji Ohno and Toru Watanabe",
year = "2012",
month = "4",
doi = "10.1159/000336480",
language = "English",
volume = "82",
pages = "131--138",
journal = "Oncology (Switzerland)",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial

T2 - The national surgical adjuvant study of breast cancer 02

AU - Ohsumi, Shozo

AU - Shimozuma, Kojiro

AU - Ohashi, Yasuo

AU - Takeuchi, Ayano

AU - Suemasu, Kimito

AU - Kuranami, Masaru

AU - Ohno, Shinji

AU - Watanabe, Toru

PY - 2012/4

Y1 - 2012/4

N2 - Objective: To elucidate the time course of taxane-induced edema which may affect the patients' quality of life (QOL). Patients and Methods: Our study included the first 300 Japanese patients assigned to 1 of 4 regimens using docetaxel (DTX) or paclitaxel (PTX) by 1:1:1:1 in a randomized controlled trial to evaluate the efficacy of adjuvant therapies for node-positive breast cancer. Patients' QOL was prospectively assessed by the Functional Assessment of Cancer Therapy (FACT)-breast and-taxane (FACT-T) subscale. The scores of FACT items regarding edema and body weight were used as indicators of edema. Results: The scores for 'anasarca', 'edema of the hands' and 'edema of the legs and feet' of the FACT-T subscale worsened up to 1-2 months after chemotherapy, and body weights increased remarkably until cycle 8 in patients treated with DTX alone (75 mg/m 2, 8 cycles, every 3 weeks). Edema-related symptoms and body weight were relatively stable in the other treatment groups. There were statistically significant differences in the scores of those items and in the changes of body weight both between the DTX-alone group and the other three groups combined, and between the groups using DTX and those using PTX. Conclusion: Many patients receiving DTX for >4 cycles suffered significantly from edema.

AB - Objective: To elucidate the time course of taxane-induced edema which may affect the patients' quality of life (QOL). Patients and Methods: Our study included the first 300 Japanese patients assigned to 1 of 4 regimens using docetaxel (DTX) or paclitaxel (PTX) by 1:1:1:1 in a randomized controlled trial to evaluate the efficacy of adjuvant therapies for node-positive breast cancer. Patients' QOL was prospectively assessed by the Functional Assessment of Cancer Therapy (FACT)-breast and-taxane (FACT-T) subscale. The scores of FACT items regarding edema and body weight were used as indicators of edema. Results: The scores for 'anasarca', 'edema of the hands' and 'edema of the legs and feet' of the FACT-T subscale worsened up to 1-2 months after chemotherapy, and body weights increased remarkably until cycle 8 in patients treated with DTX alone (75 mg/m 2, 8 cycles, every 3 weeks). Edema-related symptoms and body weight were relatively stable in the other treatment groups. There were statistically significant differences in the scores of those items and in the changes of body weight both between the DTX-alone group and the other three groups combined, and between the groups using DTX and those using PTX. Conclusion: Many patients receiving DTX for >4 cycles suffered significantly from edema.

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Chemotherapy-induced edema

KW - Quality of life

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=84862792772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862792772&partnerID=8YFLogxK

U2 - 10.1159/000336480

DO - 10.1159/000336480

M3 - Article

VL - 82

SP - 131

EP - 138

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

SN - 0030-2414

IS - 3

ER -